What’s behind Indian pharma cos’ global acquisition spree
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
Biocon shares declined as much as 2.4% to ₹262.40 on Wednesday, hitting its lowest level since November 2019.
Dalal Street is expected to see a subdued opening on Wednesday, tracking losses across Asia and Wall Street ahead of the U.S. Federal Reserve policy decision.
The Sensex and the Nifty are set to open flat on Wednesday as mixed cues from global peers overshadowed a sharp fall in crude prices overnight.
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
The BSE Sensex and the NSE Nifty are poised to open lower on Friday, following weak global cues and negative trends on SGX Nifty.
The BSE Sensex and the NSE Nifty are expected to open higher on Monday as trends on SGX Nifty indicate a gap-up opening for the Indian share market.
The BSE Sensex and the NSE Nifty are headed for a flat opening on Friday amid a mixed trend in global markets.
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Biocon Biologics targets to tap a $30 billion U.S. insulin market with two interchangeable insulins.